News | May 25, 2026
SMS Pharma posts 48% profit surge in FY26 as margins expand & portfolio shift drives growth
Revenue from operations climbed 13% to Rs. 886.87 crore
Revenue from operations climbed 13% to Rs. 886.87 crore
Nearly one in five women worldwide are now living with obesity
The pharmaceutical segment led growth, generating Rs. 337 crore in revenue, while the crop protection business contributed Rs. 157 crore
Topiramate Extended-Release Capsules are bioequivalent to the reference listed drug (RLD), Trokendi XR Extended-Release Capsules of Supernus Pharmaceuticals
Immunology remained AbbVie’s largest and fastest-growing segment, delivering $30.41 billion in global net revenues,
TMS offers new hope to patients suffering from stroke, migraine, neuropathic pain, depression, and other disorders
Sumatriptan injection is indicated in adults for the acute treatment of migraine
Four FDA-approved products strengthen portfolio and reaffirm commitment to global reach
TEMPLE, a Phase 3 multicenter, randomized, double-blind, head-to-head study, evaluated the tolerability, safety and efficacy of atogepant compared to topiramate for the preventive treatment of migraine in adult patients with a history of four or more migraine days per month
Topiramate is indicated as a treatment of epilepsy and migraine
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
